Comprehensive Stock Comparison
Compare Armata Pharmaceuticals, Inc. (ARMP) vs Regeneron Pharmaceuticals, Inc. (REGN) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  ARMP | 14.2% revenue growth vs REGN's 1.0% |
| Quality / Margins |  REGN | 31.4% net margin vs ARMP's -9.3% |
| Stability / Safety | ARMP | Beta 0.21 vs REGN's 0.58 |
| Dividends | REGN | 0.4% yield; 1-year raise streak; ARMP pays no meaningful dividend |
| Momentum (1Y) | ARMP | +432.5% vs REGN's +16.1% |
| Efficiency (ROA) | REGN | 11.1% ROA vs ARMP's -52.4%, ROIC 12.4% vs -44.2% |
Who Each Stock Is For
Income & stability
ARMPDividend streak 0 yrs, beta 0.21
Growth exposure
ARMPRev growth 14.2%, EPS growth 72.6%, 3Y rev CAGR 5.0%
Long-term compounding (10Y)
REGN94.4% 10Y total return vs ARMP's -98.1%
Sleep-well-at-night portfolio
ARMPLower volatility, beta 0.21, current ratio 0.23x
Defensive / Recession hedge
ARMPBeta 0.21, current ratio 0.23x
Business Model
What each company does and how it makes money
Armata Pharmaceuticals is a clinical-stage biotech company developing targeted bacteriophage therapies to treat antibiotic-resistant bacterial infections. It generates revenue primarily through research collaborations and partnerships — like its Merck deal — while advancing its pipeline of phage-based candidates through clinical trials. The company's key advantage is its proprietary bacteriophage platform technology, which offers a novel approach to targeting specific drug-resistant pathogens.
Regeneron Pharmaceuticals is a biotechnology company that discovers, develops, and commercializes innovative medicines for serious diseases. It generates revenue primarily from sales of its flagship products — EYLEA for eye diseases (~60% of revenue) and Dupixent for inflammatory conditions (~30%) — with additional income from collaborations and royalties. The company's competitive advantage lies in its proprietary VelocImmune technology platform for creating human antibodies and its deep expertise in genetic research, which enables rapid drug discovery and development.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
REGN 3ARMP 1REGN6/6 metricsREGN6/7 metricsARMP5/6 metricsREGN1/1 metricsREGN leads in 3 of 6 categories (Financial Metrics, Profitability & Efficiency). ARMP leads in 1 (Total Returns). 2 tied.
Financial Metrics (TTM)
REGN is the larger business by revenue, generating $14.3B annually — 2837.9x ARMP's $5M. REGN is the more profitable business, keeping 31.4% of every revenue dollar as net income compared to ARMP's -9.3%. On growth, REGN holds the edge at +2.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ARMPArmata Pharmaceut… | REGNRegeneron Pharmac… |
|---|---|---|
| RevenueTrailing 12 months | $5M | $14.3B |
| EBITDAEarnings before interest/tax | -$32M | $4.2B |
| Net IncomeAfter-tax profit | -$47M | $4.5B |
| Free Cash FlowCash after capex | -$27M | $3.2B |
| Gross MarginGross profit ÷ Revenue | +70.5% | +86.3% |
| Operating MarginEBIT ÷ Revenue | -6.6% | +25.7% |
| Net MarginNet income ÷ Revenue | -9.3% | +31.4% |
| FCF MarginFCF ÷ Revenue | -5.4% | +22.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -61.0% | +2.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -3.9% | -2.5% |
Valuation Metrics
| Metric | ARMPArmata Pharmaceut… | REGNRegeneron Pharmac… |
|---|---|---|
| Market CapShares × price | $40M | $107.4B |
| Enterprise ValueMkt cap + debt − cash | $157M | $91.3B |
| Trailing P/EPrice ÷ TTM EPS | -20.97x | 18.82x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 17.23x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.97x |
| EV / EBITDAEnterprise value multiple | — | 21.60x |
| Price / SalesMarket cap ÷ Revenue | 7.68x | 7.49x |
| Price / BookPrice ÷ Book value/share | — | 2.71x |
| Price / FCFMarket cap ÷ FCF | — | 26.32x |
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), REGN scores 7/9 vs ARMP's 2/9, reflecting strong financial health.
| Metric | ARMPArmata Pharmaceut… | REGNRegeneron Pharmac… |
|---|---|---|
| ROE (TTM)Return on equity | — | +14.4% |
| ROA (TTM)Return on assets | -52.4% | +11.1% |
| ROICReturn on invested capital | -44.2% | +12.4% |
| ROCEReturn on capital employed | -70.7% | +10.8% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 7 |
| Debt / EquityFinancial leverage | — | 0.09x |
| Net DebtTotal debt minus cash | $117M | -$16.2B |
| Cash & Equiv.Liquid assets | $9M | $18.9B |
| Total DebtShort + long-term debt | $127M | $2.7B |
| Interest CoverageEBIT ÷ Interest expense | -2.12x | 120.42x |
Total Returns (with DRIP)
A $10,000 investment in ARMP five years ago would be worth $21,301 today (with dividends reinvested), compared to $17,470 for REGN. Over the past 12 months, ARMP leads with a +432.5% total return vs REGN's +16.1%. The 3-year compound annual growth rate (CAGR) favors ARMP at 53.0% vs REGN's 0.2% — a key indicator of consistent wealth creation.
| Metric | ARMPArmata Pharmaceut… | REGNRegeneron Pharmac… |
|---|---|---|
| YTD ReturnYear-to-date | +67.2% | +0.7% |
| 1-Year ReturnPast 12 months | +432.5% | +16.1% |
| 3-Year ReturnCumulative with dividends | +258.5% | +0.6% |
| 5-Year ReturnCumulative with dividends | +113.0% | +74.7% |
| 10-Year ReturnCumulative with dividends | -98.1% | +94.4% |
| CAGR (3Y)Annualised 3-year return | +53.0% | +0.2% |
Risk & Volatility
ARMP is the less volatile stock with a 0.21 beta — it tends to amplify market swings less than REGN's 0.58 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. REGN currently trades 95.1% from its 52-week high vs ARMP's 67.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ARMPArmata Pharmaceut… | REGNRegeneron Pharmac… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.21x | 0.58x |
| 52-Week HighHighest price in past year | $16.34 | $821.11 |
| 52-Week LowLowest price in past year | $0.90 | $476.49 |
| % of 52W HighCurrent price vs 52-week peak | +67.1% | +95.1% |
| RSI (14)Momentum oscillator 0–100 | 69.6 | 52.7 |
| Avg Volume (50D)Average daily shares traded | 39K | 666K |
Analyst Outlook
Wall Street rates ARMP as "Buy" and REGN as "Buy". Consensus price targets imply 9.8% upside for REGN (target: $857) vs -18.0% for ARMP (target: $9). REGN is the only dividend payer here at 0.44% yield — a key consideration for income-focused portfolios.
| Metric | ARMPArmata Pharmaceut… | REGNRegeneron Pharmac… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $9.00 | $857.17 |
| # AnalystsCovering analysts | 4 | 48 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | 0 | 1 |
| Dividend / ShareAnnual DPS | — | $3.41 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +3.2% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Mar 26 | Change |
|---|---|---|---|
| Armata Pharmaceutic… (ARMP) | 100 | 283.46 | +183.5% |
| Regeneron Pharmaceu… (REGN) | 100 | 158.18 | +58.2% |
Armata Pharmaceutic… (ARMP) returned +113% over 5 years vs Regeneron Pharmaceu… (REGN)'s +75%. A $10,000 investment in ARMP 5 years ago would be worth $21,301 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Armata Pharmaceutic… (ARMP) | $260000.00 | $5M | +1890.0% |
| Regeneron Pharmaceu… (REGN) | $4.9B | $14.3B | +195.1% |
Regeneron Pharmaceuticals, Inc.'s revenue grew from $4.9B (2016) to $14.3B (2025) — a 12.8% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Armata Pharmaceutic… (ARMP) | -72.5% | -3.7% | +95.0% |
| Regeneron Pharmaceu… (REGN) | 18.4% | 31.4% | +70.5% |
Regeneron Pharmaceuticals, Inc.'s net margin went from 18% (2016) to 31% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Regeneron Pharmaceu… (REGN) | 36.4 | 18.6 | -48.9% |
Regeneron Pharmaceuticals, Inc. has traded in a 9x–36x P/E range over 9 years; current trailing P/E is ~19x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Armata Pharmaceutic… (ARMP) | -345.8 | -0.52 | +99.8% |
| Regeneron Pharmaceu… (REGN) | 7.7 | 41.48 | +438.7% |
Regeneron Pharmaceuticals, Inc.'s EPS grew from $7.70 (2016) to $41.48 (2025) — a 21% CAGR.
Chart 6Free Cash Flow — 5 Years
Armata Pharmaceuticals, Inc. generated $-39M FCF in 2024 (-58% vs 2021). Regeneron Pharmaceuticals, Inc. generated $4B FCF in 2025 (-38% vs 2021).
ARMP vs REGN: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ARMP or REGN a better buy right now?
Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 18.8x trailing P/E (17.2x forward), making it the more compelling value choice. Analysts rate Armata Pharmaceuticals, Inc. (ARMP) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ARMP or REGN?
Over the past 5 years, Armata Pharmaceuticals, Inc. (ARMP) delivered a total return of +113.0%, compared to +74.7% for Regeneron Pharmaceuticals, Inc. (REGN). A $10,000 investment in ARMP five years ago would be worth approximately $21K today (assuming dividends reinvested). Over 10 years, the gap is even starker: REGN returned +94.4% versus ARMP's -98.1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ARMP or REGN?
By beta (market sensitivity over 5 years), Armata Pharmaceuticals, Inc. (ARMP) is the lower-risk stock at 0.21β versus Regeneron Pharmaceuticals, Inc.'s 0.58β — meaning REGN is approximately 171% more volatile than ARMP relative to the S&P 500.
04Which has better profit margins — ARMP or REGN?
Regeneron Pharmaceuticals, Inc. (REGN) is the more profitable company, earning 31.4% net margin versus -365.6% for Armata Pharmaceuticals, Inc. — meaning it keeps 31.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 25.7% versus -820.2% for ARMP. At the gross margin level — before operating expenses — REGN leads at 86.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is ARMP or REGN more undervalued right now?
Analyst consensus price targets imply the most upside for REGN: 9.8% to $857.17.
06Which pays a better dividend — ARMP or REGN?
In this comparison, REGN (0.4% yield) pays a dividend. ARMP does not pay a meaningful dividend and should not be held primarily for income.
07Is ARMP or REGN better for a retirement portfolio?
For long-horizon retirement investors, Armata Pharmaceuticals, Inc. (ARMP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.21)). Both have compounded well over 10 years (ARMP: -98.1%, REGN: +94.4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ARMP and REGN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.